Bamboo Joint-Like Appearance of the Stomach: A Stable Endoscopic Landmark for Crohn's Disease Regardless of Anti-Tumor Necrosis Factor alpha Treatment

被引:0
|
作者
Hashiguchi, Keiichi [1 ]
Takeshima, Fuminao [1 ]
Akazawa, Yuko [1 ]
Matsushima, Kayoko [1 ]
Minami, Hitomi [1 ]
Yamaguchi, Naoyuki [1 ]
Shiozawa, Ken [1 ]
Ohnita, Ken [1 ]
Ichikawa, Tatsuki [1 ]
Isomoto, Hajime [1 ]
Nakao, Kazuhiko [1 ]
机构
[1] Nagasaki Univ, Grad Sch Biomed Sci, Dept Gastroenterol & Hepatol, Nagasaki 852, Japan
来源
MEDICAL SCIENCE MONITOR | 2014年 / 20卷
关键词
Crohn's Disease; Diagnosis; Endoscopy; Gastrointestinal; UPPER GASTROINTESTINAL-TRACT; INFLAMMATORY-BOWEL-DISEASE; GASTRIC BODY; INFLIXIMAB; CHILDREN; THERAPY; LESIONS; CARDIA; TRIAL;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Bamboo joint-like appearance is a common yet easy-to-miss endoscopic finding in the stomach of patients with Crohn's disease (CD). Bamboo joint-like appearance (BJA) is characterized by swollen longitudinal folds transversed by erosive fissures or linear furrows. However, whether BJA is observed during the remission stage of CD and during the active stage is unclear. In particular, the relationship between the course of BJA and anti-tumor necrosis factor (TNF) alpha therapy has not been studied. We aimed to evaluate the course of BJA in CD patients treated with anti-TNF alpha therapy. Material/Methods: We examined 22 CD patients who underwent esophagogastroduodenal endoscopy before undergoing anti-TNF a treatment. We evaluated the changes in BJA, clinical activity using the CD activity index (CDAI), and endoscopic activity using the simple endoscopic score for CD (SES-CD) from 6 months to 1 year after anti-TNF alpha therapy. Results: Fifteen of 22 patients (68.1%) presented with BJA in the stomach, 13 of whom received follow-up esophagogastroduodenal endoscopy after anti-TNF alpha therapy. The mean CDAI and SES-CD scores significantly improved after anti-TNF alpha therapy (P<0.01). Despite the marked improvements in clinical and endoscopic findings, the BJA of the stomach remained unchanged in all the patients. Conclusions: The findings indicate that BJA is frequently observed in the stomach of CD patients, regardless of whether the patient has active disease or is in remission, even after anti-TNF alpha therapy. Thus, BJA may be a stable endoscopic landmark in CD.
引用
收藏
页码:1918 / 1924
页数:7
相关论文
共 50 条
  • [21] Use of Vitamin D With Anti-Tumor Necrosis Factor Therapy for Crohn's Disease
    Bafutto, Mauro
    Oliveira, Enio Chaves
    Rezende Filho, Joffre
    GASTROENTEROLOGY RESEARCH, 2020, 13 (03) : 101 - 106
  • [22] Do Not Assume Symptoms Indicate Failure of Anti-Tumor Necrosis Factor Therapy in Crohn's Disease
    Bruining, David H.
    Sandborn, William J.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2011, 9 (05) : 395 - 399
  • [23] Anti-Tumor Necrosis Factor-Alpha-Loaded Microspheres as a Prospective Novel Treatment for Crohn's Disease Fistulae
    Foong, Keen Shawn
    Patel, Rishni
    Forbes, Alastair
    Day, Richard M.
    TISSUE ENGINEERING PART C-METHODS, 2010, 16 (05) : 855 - 864
  • [24] Use of Anti-Tumor Necrosis Factors and Anti-Integrins in the Treatment of Crohn's Disease
    Shivashankar, Raina
    Pardi, Darrell S.
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2017, 46 (03) : 589 - +
  • [25] Effectiveness and Safety of lmmunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease
    Osterman, Mark T.
    Haynes, Kevin
    Delzell, Elizabeth
    Zhang, Jie
    Bewtra, Meenakshi
    Brensinger, Colleen M.
    Chen, Lang
    Xie, Fenglong
    Curtis, Jeffrey R.
    Lewis, James D.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (07) : 1293 - +
  • [26] Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn's disease
    Buisson, Anthony
    Cannon, Lisa
    Umanskiy, Konstantin
    Hurst, Roger D.
    Hyman, Neil H.
    Sakuraba, Atsushi
    Pekow, Joel
    Dalal, Sushila
    Cohen, Russell D.
    Pereira, Bruno
    Rubin, David T.
    INTESTINAL RESEARCH, 2022, 20 (03) : 303 - +
  • [27] Practice Patterns in the Use of Anti-Tumor Necrosis Factor Alpha Agents in the Management of Crohn's Disease: A US National Practice Survey Comparing Experts and Non-Experts
    Swaminath, Arun
    Lebwohl, Benjamin
    Capiak, Kristina M.
    Present, Daniel H.
    DIGESTIVE DISEASES AND SCIENCES, 2011, 56 (04) : 1160 - 1164
  • [28] Mechanism and Therapeutic Strategy of Secondary Failure to Anti-Tumor Necrosis Factor-α Monoclonal Antibody Treatment for Crohn's Disease
    Matsuoka, Katsuyoshi
    Kanai, Takanori
    DIGESTION, 2013, 88 (01) : 17 - 19
  • [29] Improvement of Work Productivity and Quality of Life with Anti-Tumor Necrosis Factor Treatment Used in Crohn's Disease in Routine Clinical Practice in Turkey
    Toruner, Murat
    Basaranoglu, Metin
    Atug, Ozlen
    Senturk, Omer
    Akyuz, Filiz
    Cekic, Cem
    Hamzaoglu, Hulya Over
    Tekin, Fatih
    Sezgin, Orhan
    Akpinar, Hale
    Celik, Aykut Ferhat
    Tezel, Ahmet
    Gokturk, Huseyin Savas
    Kav, Taylan
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2022, 33 (05) : 406 - 413
  • [30] Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease
    Uri Netz
    Jane Victoria Carter
    Maurice Robert Eichenberger
    Gerald Wayne Dryden
    Jianmin Pan
    Shesh Nath Rai
    Susan Galandiuk
    World Journal of Gastroenterology, 2017, 23 (27) : 4958 - 4967